Abeta aggregation and possible implications in Alzheimer's disease pathogenesis.
Amyloid beta protein (Abeta) has been associated with Alzheimer's disease (AD) because it is a major component of the extracellular plaque found in AD brains. Increased Abeta levels correlate with the cognitive decline observed in AD. Sporadic AD cases are thought to be chiefly associated with lack of Abeta clearance from the brain, unlike familial AD which shows increased Abeta production. Abeta aggregation leading to deposition is an essential event in AD. However, the factors involved in Abeta aggregation and accumulation in sporadic AD have not been completely characterized. This review summarizes studies that have examined the factors that affect Abeta aggregation and toxicity. By necessity these are studies that are performed with recombinant-derived or chemically synthesized Abeta. The studies therefore are not done in animals but in cell culture, which includes neuronal cells, other mammalian cells and, in some cases, non-mammalian cells that also appear susceptible to Abeta toxicity. An understanding of Abeta oligomerization may lead to better strategies to prevent AD.
CSIRO Molecular and Health Technologies and P-Health Flagship, 343 Royal Parade, Parkville, Victoria, Australia.
Prashant R
PR
Bharadwaj
Ashok K
AK
Dubey
Colin L
CL
Masters
Ralph N
RN
Martins
Ian G
IG
Macreadie
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000737:chemistry* / Q000378:metabolism*; D000818:Animals; D006801:Humans; D058225:Plaque, Amyloid / Q000473:pathology; D017510:Protein Folding; D020836:Protein Structure, Quaternary
D016229:Amyloid beta-Peptides